KWANGDONG PHARMACEUTICAL CO.,LTD Q3 operating profit KRW 7.0 billion, down 35.2% from a year earlier
KAI summary · Not investment advice
Kwangdong Pharmaceutical sold KRW 460.6 billion in Q3 and earned KRW 7.0 billion from its main business, down 35.2% from a year earlier and up 149.4% from the previous quarter.
Operating profit · 3 months
KRW 7.0 billion
Key facts
- Revenue (3 months)
- KRW 460.6 billion
- Net income (3 months)
- KRW 657.2 million
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 444.5 billion
- Revenue (year to date)
- KRW 1.3 trillion
- Operating profit (prior-year 3 months)
- KRW 10.9 billion
- Operating profit (year to date)
- KRW 17.4 billion
- Net income (prior-year 3 months)
- KRW 11.1 billion
- Net income (year to date)
- KRW 8.7 billion
Commentary
AI commentary · Not investment advice
What happened
Kwangdong Pharmaceutical reported its consolidated results for the third quarter of 2026. Sales for the 3 months were KRW 460.6 billion. That is 3.6% more than the same 3 months a year earlier (KRW 444.5 billion) and 4.7% more than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was KRW 7.0 billion. That is 35.2% less than a year earlier (KRW 10.9 billion). It is 149.4% more than the previous quarter.
What changes for shareholders
Net income (the final profit after taxes and other costs) for the 3 months was KRW 0.7 billion. That is 94.1% less than a year earlier (KRW 11.1 billion) and 79.2% less than the previous quarter.
For the year to date (January 1 to September 30), sales were KRW 1,311.3 billion. Operating profit was KRW 17.4 billion, and net income was KRW 8.7 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist